Table 1. Expression intensity of CXCL16/CXCR6 and CXCL12/CXCR4 protein in human lung cancer tissues.
| Sample | Type | CXCL16 | CXCR6 | CXCL12 | CXCR4 |
| 1 | A | − | ++++ | ++++ | ++ |
| 2 | A | + | ++++ | ++++ | ++++ |
| 3 | A | + | ++++ | ++++ | ++++ |
| 4 | A | − | ++++ | ++++ | ++++ |
| 5 | A | − | ++++ | ++ | ++ |
| 6 | A | − | ++++ | ++++ | − |
| 7 | A | − | ++++ | ++++ | ++ |
| 8 | A | +++ | ++ | ++ | ++ |
| 9 | A | ++ | +++ | ++++ | + |
| 10 | A | ++ | ++++ | ++++ | ++++ |
| 11 | A | − | ++++ | ++++ | ++++ |
| 12 | A | − | ++++ | ++++ | + |
| 13 | A | + | ++++ | ++++ | ++++ |
| 14 | S | ++++ | + | ++++ | +++ |
| 15 | S | ++++ | ++++ | − | ++++ |
| 16 | S | + | + | − | − |
| 17 | S | ++++ | ++ | ++++ | + |
| 18 | S | ++++ | ++++ | ++++ | ++++ |
| 19 | S | + | + | − | + |
| 20 | S | ++ | ++++ | ++++ | ++ |
| 21 | S | − | ++++ | ++ | + |
| 22 | S | + | ++++ | ++++ | ++++ |
| 23 | S | ++ | ++++ | ++++ | ++++ |
| 24 | S | ++++ | ++++ | − | ++++ |
| 25 | S | − | ++ | − | ++ |
| 26 | AS | ++ | ++++ | ++++ | ++++ |
| 27 | AS | ++++ | ++++ | ++++ | − |
| 28 | AS | ++ | ++++ | + | + |
| 29 | AS | + | ++++ | ++++ | ++++ |
| 30 | AS | ++ | ++++ | ++++ | ++++ |
| 31 | AS | − | ++++ | ++++ | + |
| 32 | AS | ++++ | ++++ | ++++ | ++ |
| 33 | BAC | + | ++++ | ++++ | ++ |
| 34 | Nor | + | + | + | + |
| 35 | Nor | ++ | + | − | + |
| 36 | Nor | ++ | + | − | + |
| 37 | Nor | ++ | + | − | ++ |
| 38 | Nor | ++ | − | + | − |
A: adenocarcinoma, S: squamous cell carcinoma, AS: adeno-squamous carcinoma, BAC: bronchioloalveolar carcinoma, Nor: normal lung tissues, −: negative, +: weak, ++∼+++: moderate, ++++: strong.